169 related articles for article (PubMed ID: 25393982)
1. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells.
Harazono Y; Kho DH; Balan V; Nakajima K; Zhang T; Hogan V; Raz A
Oncotarget; 2014 Oct; 5(20):9992-10001. PubMed ID: 25393982
[TBL] [Abstract][Full Text] [Related]
2. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
De Rose F; Braeuer M; Braesch-Andersen S; Otto AM; Steiger K; Reder S; Mall S; Nekolla S; Schwaiger M; Weber WA; Bartolazzi A; D'Alessandria C
J Nucl Med; 2019 Jun; 60(6):770-776. PubMed ID: 30361380
[TBL] [Abstract][Full Text] [Related]
4. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
Lin CI; Whang EE; Abramson MA; Donner DB; Bertagnolli MM; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2009 Feb; 379(2):626-31. PubMed ID: 19124005
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer.
Lin CI; Whang EE; Donner DB; Jiang X; Price BD; Carothers AM; Delaine T; Leffler H; Nilsson UJ; Nose V; Moore FD; Ruan DT
Mol Cancer Res; 2009 Oct; 7(10):1655-62. PubMed ID: 19825987
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.
Trimboli P; Virili C; Romanelli F; Crescenzi A; Giovanella L
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800068
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
Fukumori T; Oka N; Takenaka Y; Nangia-Makker P; Elsamman E; Kasai T; Shono M; Kanayama HO; Ellerhorst J; Lotan R; Raz A
Cancer Res; 2006 Mar; 66(6):3114-9. PubMed ID: 16540661
[TBL] [Abstract][Full Text] [Related]
9. Gal-3 does not suppress cisplatin-induced apoptosis in A-375 melanoma cells.
Pokrywka M; Bubka M; Janik M; Pocheć E; Hoja-Łukowicz D; Lityńska A
Cell Biol Int; 2016 Apr; 40(4):428-38. PubMed ID: 26800112
[TBL] [Abstract][Full Text] [Related]
10. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis.
Zhuo Y; Chammas R; Bellis SL
J Biol Chem; 2008 Aug; 283(32):22177-85. PubMed ID: 18676377
[TBL] [Abstract][Full Text] [Related]
11. Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.
Huang CX; Hou YH; Liu YS
Neurosci Bull; 2008 Feb; 24(1):34-8. PubMed ID: 18273074
[TBL] [Abstract][Full Text] [Related]
12. A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.
Labrie M; Vladoiu M; Leclerc BG; Grosset AA; Gaboury L; Stagg J; St-Pierre Y
PLoS One; 2015; 10(7):e0131307. PubMed ID: 26168167
[TBL] [Abstract][Full Text] [Related]
13. Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1.
Fanfone D; Despretz N; Stanicki D; Rubio-Magnieto J; Fossépré M; Surin M; Rorive S; Salmon I; Vander Elst L; Laurent S; Muller RN; Saussez S; Burtea C
Med Oncol; 2017 Oct; 34(11):184. PubMed ID: 28986753
[TBL] [Abstract][Full Text] [Related]
14. Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells.
Liang N; Song X; Xie J; Xu D; Liu F; Yu X; Tian Y; Liu Z; Qiao L; Zhang J
Mol Med Rep; 2015 Feb; 11(2):896-902. PubMed ID: 25373317
[TBL] [Abstract][Full Text] [Related]
15. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis.
Fukumori T; Takenaka Y; Yoshii T; Kim HR; Hogan V; Inohara H; Kagawa S; Raz A
Cancer Res; 2003 Dec; 63(23):8302-11. PubMed ID: 14678989
[TBL] [Abstract][Full Text] [Related]
16. Reduction of galectin-3 expression reduces pituitary tumor cell progression.
Huang CX; Zhao JN; Zou WH; Li JJ; Wang PC; Liu CH; Wang YB
Genet Mol Res; 2014 Aug; 13(3):6892-8. PubMed ID: 25177969
[TBL] [Abstract][Full Text] [Related]
17. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid.
Manivannan P; Siddaraju N; Jatiya L; Verma SK
Indian J Biochem Biophys; 2012 Oct; 49(5):392-4. PubMed ID: 23259327
[TBL] [Abstract][Full Text] [Related]
18. Glycan-Dependent Mutual and Reversible Sequestration of Two Thyroid Cancer Biomarkers.
Fan N; Talaga ML; Brown RK; Fueri AL; Bandyopadhyay P; Dam TK
Thyroid; 2015 Dec; 25(12):1339-46. PubMed ID: 26421933
[TBL] [Abstract][Full Text] [Related]
19. Expression of apoptosis-related proteins in thyroid tumors and thyroid carcinoma cell lines.
Bröcker M; de Buhr I; Papageorgiou G; Schatz H; Derwahl M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():20-3. PubMed ID: 8980994
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of galectin-3 in thyroid cancer.
Chiu CG; Strugnell SS; Griffith OL; Jones SJ; Gown AM; Walker B; Nabi IR; Wiseman SM
Am J Pathol; 2010 May; 176(5):2067-81. PubMed ID: 20363921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
